Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

3 articles from the last 90 days matching "treatment approach"

ResearchRSS4 days ago

Targeting JNK pathway may offer new treatment approach for SMA

Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.

WHY IT MATTERSIf this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
👁 Watch this spacespinal muscular atrophyRead →
ResearchCLINICALTRIALSMar 26

Trial Now Recruiting: Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia (NCT07247279)

Researchers are studying how doctors treat a rare muscle weakness disease called generalized myasthenia gravis (gMG) in Russia. They want to understand what treatments work best in real-world practice by following 450 patients over time. This study is not testing a new drug, but rather collecting information about treatments that are already being used.

WHY IT MATTERSIf you have AChR-antibody positive generalized myasthenia gravis in Russia, this study could help doctors understand which current treatment approaches work best for patients like you in your region.
Good to knowGeneralized Myasthenia GravisAChR-Antibody Positive Myasthenia GravisRead →
ResearchCLINICALTRIALSMar 26

Trial Completed: Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 (NCT02116764)

Researchers completed a study following 137 patients with Chronic Granulomatous Disease (CGD), a rare immune system disorder. The study compared patients who received a bone marrow transplant (a procedure to replace damaged blood-forming cells) to patients who received standard medical care instead. This research helps doctors understand which treatment approach works best for CGD patients.

WHY IT MATTERSThis completed analysis provides real-world evidence comparing bone marrow transplant outcomes to standard care for CGD patients, which can help your doctor recommend the most effective treatment strategy for your specific situation.
💬 Ask your doctorChronic Granulomatous DiseaseRead →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases